Trinity compound research profile
BPC-157
A synthetic peptide fragment studied primarily in preclinical tissue-repair, gastrointestinal, vascular, and inflammatory models.
Research overview
BPC-157 is a synthetic peptide fragment that has been investigated mainly in laboratory and animal models involving tissue repair, gastrointestinal biology, vascular signaling, and inflammatory pathways.
Human evidence is limited compared with the volume of preclinical discussion surrounding the compound. Trinity separates published evidence from supplemental and community material so researchers can distinguish stronger findings from preliminary claims.
Human evidence summary
Human evidence is minimal. A few very early-stage trials tested BPC-157 in people with ulcerative colitis and multiple sclerosis, mainly to check that it was safe, but researchers haven't run a proper large trial to prove it actually speeds up healing in humans (Front Pharmacol 2021; Pharmaceuticals 2025 review). An important limitation: almost all of the research on BPC-157 comes from one research group based in Zagreb, Croatia, meaning other scientists haven't independently repeated and confirmed these findings.
Preclinical evidence summary
This is where almost all the solid evidence lives. In rats and mice, BPC-157 sped up the healing of skin wounds, tendons, ligaments, muscles, bones, the cornea of the eye, and the stomach/intestine lining (Front Pharmacol 2021). Animal toxicity testing found no dose high enough to cause death, which suggests a wide safety margin in animals — though that doesn't automatically mean it's equally safe in people.
Source material
Use the linked publications and records to evaluate study design, population, limitations, and relevance.